Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases

Salazar, Lupe G.; Lu, Hailing; Reichow, Jessica; Childs, Jennifer S.; Coveler, Andrew L.; Higgins, Doreen M.; Waisman, James; Allison, Kimberly H.; Dang, Yushe; Disis, Mary L.

doi:10.1001/jamaoncol.2016.6007

Cited by 84 publications

(60 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Six out of 8 subjects showed partial responses or stable diseases, and tumor regression was associated with the presence of tumor-infiltrating CD4 + and CD8 + T cells [59]. In a Phase II breast cancer trial, 15 subjects applied Imiquimod topically to targeted lesions on 4 consecutive days per week for 12 weeks [60]. Albumin bound paclitaxel (100mg/m 2 ) was also given intravenously once weekly for 3 weeks and repeated every 28 days for 12 weeks.…”

Section: Targeting Pdcs With Tlr7/8 Agonistsmentioning

confidence: 99%

See 1 more Smart Citation

In vivo cancer vaccination: Which dendritic cells to target and how?

Chiang¹,

Kandalaft²

2018

Cancer Treatment Reviews

View full text Add to dashboard Cite

The field of cancer immunotherapy has been revolutionized with the use of immune checkpoint blockade antibodies such as anti-programmed cell death 1 protein (PD-1) and chimeric antigen receptor T cells. Significant clinical benefits are observed in different cancer types with these treatments. While considerable efforts are made in augmenting tumor-specific T cell responses with these therapies, other immunotherapies that actively stimulate endogenous anti-tumor T cells and generating long-term memory have received less attention. Given the high cost of cancer immunotherapies especially with chimeric antigen receptor T cells, not many patients will have access to such treatments. The next-generation of cancer immunotherapy could entail in vivo cancer vaccination to activate both the innate and adaptive anti-tumor responses. This could potentially be achieved via in vivo targeting of dendritic cells which are an indispensable link between the innate and adaptive immunities. Dendritic cells highly expressed toll-like receptors for recognizing and eliminating pathogens. Synthetic toll-like receptors agonists could be synthesized at a low cost and have shown promise in preclinical and clinical trials. As different subsets of human dendritic cells exist in the immune system, activation with different toll-like receptor agonists could exert profound effects on the quality and magnitude of anti-tumor T cell responses. Here, we reviewed the different subsets of human dendritic cells. Using published preclinical and clinical cancers studies available on PubMed, we discussed the use of clinically approved and emerging toll-like receptor agonists to activate dendritic cells in vivo for cancer immunotherapy. Finally, we searched www.clinicaltrials.gov and summarized the active cancer trials evaluating toll-like receptor agonists as an adjuvant.

show abstract

Section: Targeting Pdcs With Tlr7/8 Agonistsmentioning

confidence: 99%

“…Albumin bound paclitaxel (100mg/m 2 ) was also given intravenously once weekly for 3 weeks and repeated every 28 days for 12 weeks. Ten subjects experienced complete and partial responses [60]. The clinical response was short-lived, suggesting that longer course of treatment was needed.…”

Section: Targeting Pdcs With Tlr7/8 Agonistsmentioning

confidence: 99%

In vivo cancer vaccination: Which dendritic cells to target and how?

Chiang¹,

Kandalaft²

2018

Cancer Treatment Reviews

View full text Add to dashboard Cite

show abstract

“…Out of total 15 patients, five complete responses and five partial responses were recorded. However, the responses lasted only for short time . For optimizing IMQ for intravesical injection, TMX‐101, a liquid formulation, was designed.…”

Section: Clinical Application Of Tlr Ligands For Cancer Treatmentmentioning

confidence: 99%

“…However, the responses lasted only for short time. 106 For optimizing IMQ for intravesical injection, TMX-101, a liquid formulation, was designed.…”

Section: Clinical Application Of Tlr Ligands For Cancer Treatmentmentioning

confidence: 99%

Basic understanding and therapeutic approaches to target toll‐like receptors in cancerous microenvironment and metastasis

Attar

Anwar

Eskian

et al. 2017

Medicinal Research Reviews

View full text Add to dashboard Cite

Toll-like receptors (TLRs) are transmembrane components that sense danger signals, like damage- and pathogen-associated molecular pattern molecules, as receptors, and maintain homeostasis in tissues. They are mainly involved in immune system activation through a variety of mediators, which either carry out (1) elimination of pathogenic threats and redressing homeostatic imbalances or (2) contribution to the initiation and worsening of pathological conditions, including cancers. Under physiological conditions, TLRs coordinate the innate and adaptive immunity, and inhibit autoimmune disorders. In pathological conditions, such as cancer, they can present both tumor and receptor-specific roles. Although the roles of individual TLRs in various cancers have been described, the effects of targeting TLRs to treat cancer and prevent metastasis are still controversial. A growing body of literature has suggested contribution of both activators and inhibitors of TLR signaling pathway for cancer treatment, dependent on several context-specific factors. In short, TLRs can play dual roles with contradictory outcomes in neoplastic conditions. This hampers the development of TLR-based therapeutic interventions. A better understanding of the interwoven TLR pathways in cancerous microenvironment is necessary to design TLR-based therapies. In this review, we consider the molecular mechanisms of TLRs signaling and their involvement in tumor progression. Therapeutic modalities targeting TLRs for cancer treatment are discussed as well.

show abstract

“…Skin-directed treatment options for CMOBC include radiotherapy (2), surgical excision (3), electrochemotherapy (4), topical imiquimod (3,5-7), either as monotherapies or combination therapies (6,8), cryotherapy (8), 5-fluorouracil (5-FU) (8), photodynamic therapy (9)(10)(11) and topical applications of miltefosine (2,12,13).…”

Section: Introductionmentioning

confidence: 99%

Cutaneous breast cancer metastases successfully treated using an oxygen flow assisted administration of methotrexate (OFAMTX5%)

Jouret

Gonne

Quatresooz

et al. 2020

Preprint

View full text Add to dashboard Cite

Introduction: Cutaneous metastases of breast cancer (CMOBC) remain a therapeutic challenge. Recently, oxygen flow assisted topical administration of methotrexate 3% (OFAMTX5%) was proven an efficacious alternative treatment for extramammary Paget’s disease, an in situ mammary adenocarcinoma. Aim: To evaluate the efficacy and tolerance of OFAMTX5% for the treatment of CMOBC. Materials and methods: A patient with triple negative breast cancer presented with biopsy proven CMOBC. Two weekly sessions were given for 2 weeks with OFAMTX5% on a site of approximately 40 cm 2 . Skin biopsies were performed before and 2 months after procedure. Results: Tolerance was excellent with no pain sensations. Two months post procedure the treated area presented a postinflammatory hyperpigmentation. No residual metastases were evidenced on the control skin biopsy. Discussion: In selected cases of CMOBC OFAMTX5% can represent a non-painfull and efficacious treatment alternative. Larger series should evaluate the place of OFAMTX5% for the treatment of CMOBC.

show abstract

Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases

Abstract: clinicaltrials.gov Identifier: NCT00821964.

Cited by 84 publications

References 16 publications

In vivo cancer vaccination: Which dendritic cells to target and how?

In vivo cancer vaccination: Which dendritic cells to target and how?

Basic understanding and therapeutic approaches to target toll‐like receptors in cancerous microenvironment and metastasis

Cutaneous breast cancer metastases successfully treated using an oxygen flow assisted administration of methotrexate (OFAMTX5%)

Contact Info

Product

Resources

About